FDA’s Final PDURS Guidance: Key Takeaways for Drug Sponsors and Software Developers
Prescription Drug Use Related Software, Drug Labeling, and Free Speech
FDA recently finalized its long-awaited guidance on prescription drug use-related software (PDURS), providing greater clarity on how digital health tools and their outputs are regulated under existing drug labeling requirements. At the same time, FDA published a nonbinding memorandum justifying its treatment of PDURS as promotional labeling from a First Amendment perspective.
Arnold & Porter will examine key changes from the draft to final PDURS guidance, implications for drug sponsors and software developers, and emerging legal and regulatory questions surrounding FDA’s oversight of drug use-related software as promotional labeling. Among other topics, the panel will discuss why sponsors can no longer assume that a software function’s low-risk or non-device status insulates its output from drug labeling review, and whether FDA’s approach can withstand First Amendment scrutiny.
We hope you’ll join us!